Search results for: 'model based system engineering big data'

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

23 Feb 2021  |  North America  |  Market Research

AI-Based Image Analysis Tools and Cloud-Based Deployment to Expand the Global Digital Pathology Market

Increased Demand for Remote Pathology Services and Centralization of Digital Pathology Workflow in Hospital Networks to Spark New Growth Opportunities

Infographics

×

The Transformational Health team at Frost & Sullivan provides critical insights into the global digital pathology market, highlighting key growth opportunities, market revenue forecast, and business models that will play an essential role in its growth. The study segments the market by product (hardware, software, and storage solutions) and region ...

16 Feb 2021  |  North America  |  Market Research

Smartphone-based Saliva Testing and Self-monitoring of Blood Glucose Driving the Digital POCT Market

Mobility Ecosystem Holds Bold Promise to Expand Patients’ Access to Care

Infographics

×

Smartphone-based devices and associated tools are becoming the ideal next-generation point-of-care testing (POCT) solutions for in vitro diagnostics. The global COVID-19 pandemic has led to frugal innovations in POCT. The World Health Organization (WHO) has endorsed POCT as the topmost research priority in response to the COVID-19 outbreak. Digital...

The COVID-19 pandemic prompted a transformation in the infectious disease point-of-care testing (POCT) market. The shift towards miniaturized POCT devices will lead to the emergence of cost-effective integrated lab-on-a-chip devices based on microfluidic technologies and smartphone-based solutions enabling multiplexed detection of infectious pathog...

03 Feb 2021  |  North America  |  Market Research

Companion Diagnostics (CDx) is Revolutionizing the Global Clinical Next-generation Sequencing (NGS) Market

Next-generation Blockchain-Powered Genomic Data Marketplaces are Creating New Growth Opportunities

Infographics

×

2020 will be remembered for the COVID-19 pandemic, masks, social distancing protocol, alternate care sites, Moderna, Pfizer, BioNTech, AstraZeneca, RT-PCR, and serology testing (or all the above). However, in the midst of our response to the global pandemic, remarkable advancements were made in another great frontier in medicine that remains unconq...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 c...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...